STOCK TITAN
  1. Home
  2. News
  3. CYAD

Celyad Oncology - CYAD STOCK NEWS

Welcome to our dedicated news page for Celyad Oncology (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on Celyad Oncology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Celyad Oncology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Celyad Oncology's position in the market.

News
Celyad Oncology Reports Full Year 2023 Financial Results and Recent Business Highlights
Rhea-AI Summary
Celyad Oncology announces financial results for 2023, highlighting strategic shifts towards innovation in immunotherapy. The company secured a private placement, developed new technologies, and achieved positive clinical outcomes. Financially, Celyad projects sufficient funds till Q2 2025, with a focus on cost reduction and operational efficiency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Celyad Oncology Announces Intention to Terminate SEC Reporting Obligations
Rhea-AI Summary
Celyad Oncology announces voluntary filing of Form 15F with the SEC to terminate its reporting obligations, maintaining listing on Euronext Brussels and Euronext Paris.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Celyad Oncology Provides Fourth Quarter 2023 Business Update and 2024 Outlook
Rhea-AI Summary
Celyad Oncology's 2023 business update highlights the progress made in broadening the range of cancer indications targeted by CAR T-cells and overcoming the main limitations of current CAR T-cell therapies. The company obtained commitments for a capital increase of up to €9.8 million, which is expected to fund operating expenses and capital expenditure requirements into the second quarter of 2025. The company also shared data validating its shRNA multiplexing approach and multispecific NKG2D-based CAR T-cell platform. As of December 31, 2023, the company had cash and cash equivalents of €3.0 million and short-term investments of €4.0 million, projected to be sufficient for funding operating expenses and capital expenditure requirements into the second quarter of 2025. The outlook for 2024 includes the sharing of more data and evidence in the context of the multispecific CAR T-cell platform and shRNA multiplexing approach.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
News
Celyad Oncology SA: Publication of a Transparency Notification Received From Fortress Investment Group LLC
Rhea-AI Summary
Celyad Oncology SA (Euronext: CYAD) received a notification of transparency indicating that CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, has crossed the statutory threshold of 55%, holding 29,358,654 voting rights, i.e. 58.37 % of Celyad Oncology’s voting rights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
Rhea-AI Summary
Celyad Oncology (CYAD) announces that 6,500,000 shares now have double voting rights, increasing the total number of voting rights to 50,296,947. The total amount of share capital is now EUR 88,378,224.25.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Celyad Announces Management Change
Rhea-AI Summary
Celyad Oncology (CYAD) announces CEO Georges Rawadi's resignation for personal reasons, effective December 1, 2023. Co-founder Michel Lussier takes over as interim CEO. The company aims to maximize the impact of its CAR T-cell therapies and redefine the future of CAR T-cell treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Celyad Oncology SA: Publication of a transparency notification received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007)
Rhea-AI Summary
Celyad Oncology SA (Euronext: CYAD) received a transparency notification from Tolefi SA and related persons indicating they have jointly crossed passively below the 15% threshold, holding 6,568,978 shares, or 14.997% of the voting rights of the Company as of November 14, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Celyad Oncology SA: Publication of a transparency notification received from Fortress Investment Group LLC
Rhea-AI Summary
Celyad Oncology SA (CYAD) received a notification of transparency indicating that CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, has crossed the statutory threshold of 50%, holding 22,858,654 shares i.e. 52.19% of Celyad Oncology’s voting rights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
Rhea-AI Summary
Celyad Oncology (CYAD) Announces Capital Increase and New Share Issuance to Affiliate of Fortress Investment Group, Resulting in Share Capital of 88,378,224.25 EUR and 41,428,572 Shares. The company has published this information in compliance with Belgian disclosure regulations, with the total number of diluted shares now at 44,467,443.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Celyad Oncology reports third quarter 2023 financial results and recent business highlights
Rhea-AI Summary
Celyad Oncology (Euronext: CYAD) reports financial results for Q3 2023, including a private placement commitment of EUR 9.8m. The company presented data on its multiplex shRNA approach and NKG2D-based multi-specific CAR T-cell platform at international conferences. The company's cash and cash equivalents are projected to fund operating expenses into Q2 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
Stock CYAD logo
Celyad Oncology

Nasdaq:CYAD

CYAD Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

CYAD Stock Data

14.24M
13.58M
0.05%
29.15%
0.58%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Belgium
Mont Saint Guibert

About CYAD

founded in 2007, celyad is a clinical-stage biopharmaceutical company that leverages unique know-how in taking cell-based therapies from bench to phase iii, as well as the manufacturing and logistical infrastructure for such complex products. celyad builds it business model on partnering with prominent research institutions such as dartmouth college, and develops those programs from bench to commercial applications. the company is currently developing clinical programs in immuno-oncology, testing natural killer receptors t-cells (nkr-t cells) for cancer treatment. a unique approach that has the potential to target and destroy a vast majority of tumor types. celyad is listed on euronext brussels, euronext paris and on nasdaq (cyad).